CD82 and breast cancer: As CD82 is known to have anti-metastatic properties (as elaborated in Section 4.1), this glycoprotein would be a good and suitable potential molecular target to be further explored for precision therapy in preventing breast cancer progression, when used in combination with systemic therapy according to the cancer subtype (as described in the above paragraph).